Loncastuximab Tesirine
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Explore 105 assets in Relapsed/Refractory Diffuse Large B-Cell Lymphoma →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
University of Utah
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06788964CT.gov Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) | — | Recruiting | — | — | — |
NCT05672251CT.gov Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT05453396CT.gov Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | — | Terminated | — | — | — |
NCT05228249CT.gov Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05222438CT.gov Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | — | Withdrawn | — | — | — |
NCT04384484CT.gov Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03589469CT.gov Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT04705454CT.gov Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Loncastuximab Tesirine (this asset) | University of Utah | P3 | CCC · 54 |
| Selinexor | Chengdu Zenitar Biomedical Technology Co., Ltd | P3 | BB |
| Dexasone | City of Hope Medical Center | P2/3 | BB |
| Etoposide | University of California, Davis | P3 | BB |
| Cyclophosphamide | Nathan Denlinger | P3 | BB |
| Isocyclophosphamide | University of California, Davis | P3 | BB |
| Axicabtagene Ciloleucel | Zhujiang Hospital | P3 | BB |
| Adriamycin | City of Hope Medical Center | P3 | BB |
| Carboplatin | University of California, Davis | P3 | BB |
+42 more in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort
Other indications for Loncastuximab Tesirine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2/3 | B · 61 |
| Marginal Zone Lymphoma | — | P2 | CCC · 55 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/loncastuximab-tesirine-relapsedrefractory-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →